Who Paid My Doc
Paul Masci
Hematology & Oncology Wooster, OH Doctor of Osteopathy
NPI 1366408627 CMS profile 458890
721 E Milltown Rd, Wooster, OH 44691
General payments
$59
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Paul Masci of Wooster, OH is reported in the CMS Open Payments database as having received $59 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 7th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $24 | 1 | |
| 2021 | General | $35 | 2 |
Beside peers
- Paul Masci
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Paul Masci were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Paul Masci | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $35 | $263 | $49–$1,965 | $132 |
| 2022 | $24 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 60 drugsPart D claims
2,164
Drug cost
$6,692,641
Branded share of claims
31.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Brukinsa Zanubrutinib | Brand | 99 | $1,329,916 | |
| Imbruvica Ibrutinib | Brand | 53 | $847,193 | |
| Lenalidomide | Generic | 58 | $838,503 | |
| Revlimid Lenalidomide | Brand | 29 | $629,186 | |
| Pomalyst Pomalidomide | Brand | 21 | $478,132 | |
| Calquence Acalabrutinib Maleate | Brand | 25 | $310,941 | |
| Scemblix Asciminib Hydrochloride | Brand | 13 | $280,865 | |
| Ibrance Palbociclib | Brand | 18 | $277,648 | |
| Xalkori Crizotinib | Brand | 13 | $247,936 | |
| Jakafi Ruxolitinib Phosphate | Brand | 27 | $225,207 |
The 10 drugs with the highest cost, of 60 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 146 billing codesPaid by Medicare
$4,705,708
Medicare patients
446
Services billed
228,885
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 47% | |
| Cancer | 46% | |
| Chronic kidney disease | 34% | |
| Diabetes | 27% | |
| Ischemic heart disease | 27% | |
| Depression | 24% | |
| Atrial fibrillation | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, nivolumab, 1 mg J9299 | Office | 11 | 27,020 | $664,908 |
| Injection, pembrolizumab, 1 mg J9271 | Office | 16 | 14,000 | $624,956 |
| Injection, denosumab, 1 mg J0897 | Office | 17 | 3,480 | $71,376 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg J2506 | Office | 11 | 600 | $31,826 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg Q5119 | Office | 11 | 1,740 | $28,567 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 12 | 103 | $14,451 |
| Injection, iron sucrose, 1 mg J1756 | Office | 28 | 24,200 | $4,199 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 56 | 541 | $2,699 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 38 | 1,670 | $1,201 |
| Injection, carboplatin, 50 mg J9045 | Office | 14 | 398 | $1,132 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Ohio
Hillard Lazarus
Hematology & Oncology · Cleveland, OH
Kasra Karamlou
Hematology & Oncology · Sandusky, OH
David Waterhouse
Hematology & Oncology · Cincinnati, OH
Taral Patel
Hematology & Oncology · Columbus, OH
Tarek Chidiac
Hematology & Oncology · Columbus, OH
Saulius Girnius
Hematology & Oncology · Montgomery, OH
Related records
Hematology & Oncology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.